Core Points - Profusa, Inc. announced a one-for-seventy-five (1:75) reverse stock split of its common stock, effective at 12:01 am (Eastern Time) on February 9, 2026 [1] - The reverse stock split will consolidate every seventy-five shares into one share, with no change in the nominal par value per share of $0.0001 [2] - Following the reverse stock split, the number of outstanding shares will decrease from approximately 92.4 million to about 1.2 million shares, while the number of authorized shares will remain at 601 million [3] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, California, focused on developing tissue-integrated sensors for continuous monitoring of biochemistry [4] - The company aims to provide personalized biochemical signatures through its long-lasting, injectable biosensors and intelligent data platform, which are designed for both personal and medical use [4]

Core Viewpoint - Hims & Hers Health, Inc. has launched the Hims & Hers Multi-Cancer Test by Galleri®, a blood test capable of detecting signals for over 50 types of cancer before symptoms appear, aiming to enhance access to proactive cancer care [1][2]. Group 1: Product Launch and Features - The Multi-Cancer Test by Galleri® can detect signals for more than 50 types of cancer, including those without recommended screenings, and is designed to be taken annually [2][3]. - The test leverages GRAIL's innovative technology to improve early detection of cancer signals in blood, predicting the likely origin of the signal in the body [3][4]. Group 2: Market Context and Importance - Over one in three individuals will develop cancer in their lifetime, with many cancers remaining undetected until later stages, which complicates treatment and worsens outcomes [1][2]. - The introduction of the Galleri test aims to address the gap in early cancer detection, particularly for aggressive cancers that are often diagnosed late [1][4]. Group 3: Pricing and Accessibility - Starting today, Hims & Hers customers can access the Multi-Cancer Test by Galleri® at a $250 discount from the list price, making it more affordable [5].

Core Viewpoint - PAVmed has successfully closed financings that eliminate all previously outstanding convertible securities, significantly strengthening its balance sheet and capital structure [1] Financing Details - The Series D Preferred Stock offering generated $30 million in gross proceeds, with warrants for an additional $30 million contingent on a positive Medicare local coverage determination for the EsoGuard test [1] - A new senior secured note with a three-year maturity raised an additional $15 million [1] - The total net cash proceeds from these transactions amount to approximately $7.7 million, which will be used for general working capital [1] Capital Structure Improvement - The proceeds from the financings were utilized to redeem all outstanding Series C Convertible Preferred Stock and fully retire existing convertible debt [1] - Assuming the exercise of associated warrants and conversion of Series D Preferred Stock, the company could achieve a clean capital structure consisting entirely of common stock and long-term debt, adding approximately $37.7 million in cash to the balance sheet [1] Strategic Positioning - PAVmed's Chairman and CEO highlighted that this transaction is a transformative outcome aimed at fixing the legacy capital structure and unlocking the company's asset strength for shareholders [1] - The company is now positioned to pursue additional commercial opportunities and enhance long-term shareholder value, leveraging its subsidiaries, including Lucid Diagnostics and Veris Health [1]

Hinge Health, Inc. (NYSE:HNGE) is one of the stocks Jim Cramer shed light on recently. Starting the lightning round, a caller inquired about the stock, and Cramer replied: … If you remember when they came on, I thought they were terrific and they are part of the solution, not the problem. I think that that is going to be one of the better stocks we’ve seen in the healthcare sector. Stock market data showing an upward trajectory. Photo by Burak The Weekender on Pexels Hinge Health, Inc. (NYSE:HNGE) dev ...

Core Viewpoint - Hydreight Technologies Inc. has provided revenue guidance for fiscal year 2026, projecting approximately $150 million in revenue, which reflects a conservative baseline outlook based on contracted demand and partner activity [2][6]. Fiscal 2026 Revenue Guidance - The company expects fiscal 2026 revenue of around $150 million, which is a conservative estimate based on existing pharmacy operations and digital health platform activities [2]. - This guidance does not include potential contributions from acquisitions, new market entries, or additional commercial arrangements that are not currently operational [2][6]. Q1 2026 Revenue Outlook - For the first quarter of fiscal 2026, the company anticipates revenue between $25 million and $28 million, driven by major partnerships and pharmacy product lines that are set to go live [3]. Cost Structure, Margin, and Profitability Context - The fiscal 2026 guidance assumes no significant increase in fixed operating costs compared to late 2025 levels, with revenue growth supported by the existing cost base [4]. - The company expects an Adjusted EBITDA margin of approximately 15-17%, benefiting from scaling transaction volumes across a largely fixed operating cost structure [5]. Management Commentary - The CEO of Hydreight emphasized that the guidance reflects the visibility into operations and is grounded in existing demand, supported by a disciplined cost structure [7]. Capital Position - The company recently completed a $15 million financing deal to enhance working capital, which is expected to support anticipated transaction volumes and ongoing operations [9].

Core Insights - Rocket Doctor AI Inc. has engaged Danayi Capital Corp. for digital marketing services for a two-month term starting February 9, 2026, with an upfront payment of USD$125,000 [1] - The company has granted a total of 33,353 stock options at an exercise price of $0.77 per share and 205,065 restricted share units to consultants, both valid for three years and subject to a one-year vesting period [3] - Rocket Doctor AI focuses on providing AI-powered healthcare solutions, aiming to improve access to quality healthcare through its proprietary technology, including the Global Library of Medicine [4][6] Company Overview - Rocket Doctor AI Inc. offers physician-built, AI-driven solutions designed to enhance the patient journey and healthcare accessibility [4] - The company has supported over 300 MDs in delivering care to more than 700,000 patient visits, enabling doctors to manage their own virtual or hybrid practices [5] - The technology aims to reduce administrative burdens, allowing for more meaningful interactions between physicians and patients, particularly in underserved communities [6]

Core Viewpoint - CIMG Inc. has announced a sales agreement through its subsidiary, Zhimeng, to supply wood chips to Yuncheng Trading, which is expected to stabilize the company's raw material supply chain and positively impact its financial performance [1][2][3]. Group 1: Sales Agreement Details - Zhimeng will supply approximately 15,000 bone-dry metric tons of wood chips, including eucalyptus, acacia, and mixed wood chips, to Yuncheng Trading, with a total contract value of approximately US$2.59 million [2]. - The delivery is expected to be completed by February 28, 2026, with a variance allowance of up to 10% on the total quantity [2]. Group 2: Strategic Implications - The sales agreement is aimed at establishing long-term, stable relationships with both upstream and downstream partners, aligning with the company's strategic development objectives [3]. - The company reports steady performance growth across all business lines, indicating a sound operational status [3]. Group 3: Company Overview - CIMG specializes in digital health and sales development, leveraging technologies and marketing networks to enhance business partners' sales growth [1]. - The company employs AI and cryptocurrencies to drive business growth, with a client portfolio that includes brands such as Kangduoyuan and Maca-Noni [4].

Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patients BERKELEY, Calif, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the presentation of positive US-study clinical trial results at Leipzig Interventional Course in Leipgzig, Germany on Wednesday, January 28, 20 ...

World Renowned Cardiologist and Research Leader to Guide Clinical Strategy, Product Innovation, and AI-Driven Cardiac Diagnostics TORONTO, ON / ACCESS Newswire / January 28, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce the appointment of Dr. Paul Dorian, MD, MSc., as the Company's Medical Innovation Architect (MIA) and Head of the Company's Medical Advisory Board, effective immediately. Dr. Dorian succeeds Peter Kendall, who previously serv ...

Rocket Doctor is now in-network with another major insurer for commercial employer-sponsored health plans across California.The new agreement includes approximately 175,000 members in California under one major insurer, extending Rocket Doctor’s total in-network reach to over 13 million members coast to coast.The agreement further strengthens Rocket Doctor’s presence in one of the largest U.S. healthcare markets and supports its national expansion strategy.The partnership enhances payer mix and positions th ...